Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

NCT05675059 | Active Not Recruiting

• 1 other identifier: MCC-22082
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to assess the feasibility and participant satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program. The program provides enhanced dietician access and nutrition support for participants living with pancreatic cancer who are receiving chemotherapy.

Conditions

Pancreatic Cancer

Outcome Measures

Primary Outcomes (6)

• Feasibility of the STRONG Program

  Feasibility of the Support through Remote Observation and Nutrition Guidance (STRONG) program will be assessed using recruitment and retention rates, along with data completion rates.

  at 12 weeks

• Acceptability of the STRONG Program

  Acceptability of the STRONG Program measure uses 4 items to indicate participant satisfaction. The measure uses a scale of 0-5, 0 meaning the participant completely disagrees with the statements regarding intervention satisfaction and 5 indicating complete agreement with the statements regarding intervention satisfaction. The measure score ranges from 0-20 with 20 indicating the highest degree of satisfaction.

  at 16 weeks

• Participant adherence to the STRONG Program

  will be defined as ≥ 60% of patients will meet with a dietician for 4/6 dietician visits and ≥ 60% of patients will track daily food intake via a Fitbit.

  Up to 90 days

• Malnutrition: Significant Weight Loss

  Significant weight loss will be defined as a loss of \>5% and \>10% of body weight over the 16 week assessment period. Weight will be measured in kg.

  at 16 weeks

• Malnutrition: Low BMI

  Low BMI will be calculated by combining weight (kg) and height measurements (m²) and defined as \<20kg/m² for adults \< 70 years old and \<22kg/m² for adults ≥ 70 years old over the 16 week assessment period.

  at 16 weeks

• Malnutrition: Low Skeletal Muscle Mass

  Low skeletal muscle mass will be calculated by estimating skeletal muscle index (SMI) by dividing the cross-sectional area of muscle in a single 'slice' from an abdominal CT scan (cm2) by stature (square of height in m²). Low SMI will be defined as ≤38.9 cm2/m2 for females and ≤55.4 for males over the 16 week assessment period.

  at 16 weeks

Study Arms (2)

Group 1: STRONG Intervention

ACTIVE COMPARATOR

The STRONG program includes consultation with a Moffit dietician, logging intake of food daily into a food diary with a Fitbit smartphone app, and completing questionnaires.

Behavioral: Consultations with Moffitt Dietician; Behavioral: Daily Food Intake Diary with Fitbit Smartphone application; Behavioral: Questionnaires

Group 2: Usual Care

ACTIVE COMPARATOR

Participants will be referred to dieticians based on clinical discretion. Participants will also be asked to wear a Fitbit for 12 weeks to passively collect data on activity level.

Behavioral: Consultations with Moffitt Dietician; Behavioral: Daily Food Intake Diary with Fitbit Smartphone application; Behavioral: Questionnaires

Interventions

Consultations with Moffitt Dietician BEHAVIORAL

Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.

Group 1: STRONG Intervention; Group 2: Usual Care

Daily Food Intake Diary with Fitbit Smartphone application BEHAVIORAL

Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.

Group 1: STRONG Intervention; Group 2: Usual Care

Questionnaires BEHAVIORAL

Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.

Group 1: STRONG Intervention; Group 2: Usual Care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older
• Diagnosed metastatic or newly recurrent pancreatic cancer or locally advanced pancreatic cancer
• Receiving chemotherapy under the guidance of Moffitt
• Able to speak and read English
• Able to provide informed consent

You may not qualify if:

• Documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., psychosis, active substance abuse).
• Undergoing concurrent treatment for a second primary GI cancer
• ECOG status of 2 or greater
• Use of parenteral or enteral nutrition
• Presence of malignant ascites

Sponsors & Collaborators

• H. Lee Moffitt Cancer Center and Research Institute: lead
• Pancreatic Cancer Action Network: collaborator

Study Sites (1)

Moffitt Cancer Center

Tampa, Florida, 33612, United States

Location

Related Publications (1)

• Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. Contemp Clin Trials Commun. 2024 Feb 23;38:101271. doi: 10.1016/j.conctc.2024.101271. eCollection 2024 Apr.

  PMID: 38440777 DERIVED

Related Links

• Moffitt Cancer Center Clinical Trials website

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

Referral and Consultation; Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Professional Practice; Organization and Administration; Health Services Administration; Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Amir Alishahi Tabriz, MD, PhD, MPH

  Moffitt Cancer Center

  PRINCIPAL INVESTIGATOR

• Pamela Hodul, MD

  Moffitt Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2022
• First Posted: January 9, 2023
• Study Start: December 21, 2022
• Primary Completion: November 22, 2025
• Study Completion (Estimated): June 1, 2026
• Last Updated: February 9, 2026

Record last verified: 2026-02

Locations

US (1)